The New Drug Application (NDA) for viloxazine hydrochloride (SPN-812; Supernus Pharmaceuticals), a serotonin norepinephrine modulating agent, has been submitted to the Food and Drug Administration (FDA) for the treatment of pediatric patients with attention deficit hyperactivity disorder (ADHD).
Increase seen for adults of every race/ethnicity; prevalence rates highest for white individuals.
Researchers found a weak signal for persistent ADHD to be more associated with 8-year follow-up of bipolar disorder than remitting ADHD.
Recommendations include screening for comorbid conditions, understanding ADHD is chronic condition.
Significant increases in prevalence of any developmental disability and in ADHD, ASD, intellectual disability.
White matter changes seen after 4 months of MPH vs placebo in boys, but not men, with ADHD.
Children with ADHD exhibit impaired stop cues and reduced engagement.
Athletes with ADHD had more symptoms at 24 to 48 hours, regardless of psychostimulant use.
Prevention programs may improve long-term outcomes in children and adolescents by addressing pre-existing vulnerabilities that increase the risk for exposure to bullying.
Odds of both ASD and ADHD increased for later-born siblings of children with either diagnosis.
This research rejects any association between increased risk for ADHD and changes in children’s microbiota related to cesarean delivery or antibiotic use.
Significant increases in prevalence in subgroups by age, sex, race/ethnicity, income, geographic region.
Association holds after adjustment for unmeasured genetic, environmental factors
Diethylstilbestrol exposure during pregnancy is associated with multigenerational neurodevelopmental deficits in childhood, including ADHD.
Co-occurrence of attention-deficit/hyperactivity disorder is common in children with autism spectrum disorder.
A study of an investigational digital medicine achieves its primary efficacy end point in pediatric ADHD.
Omega-3 supplementation in children with mood disorders is associated with decreased impairment in executive functioning.
Cerebral morphometric alterations can discriminate between children with attention-deficit/hyperactivity disorder and controls.
Women with significant attention-deficit/hyperactivity disorder do not need to stop treatment during pregnancy.
Treatment with ADHD medication during pregnancy was associated with a higher risk for neonatal morbidity, especially central nervous system-related disorders such as seizures.